标题
Managing Risks with Immune Therapies in Multiple Sclerosis
作者
关键词
-
出版物
DRUG SAFETY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-03
DOI
10.1007/s40264-018-0782-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis
- (2018) Caila Vaughn et al. CNS DRUGS
- Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
- (2018) Virginia Devonshire et al. JOURNAL OF NEUROLOGY
- 039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets
- (2018) Stuart Cook et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Understanding risk of PML through multiple sclerosis
- (2018) Roland Martin LANCET NEUROLOGY
- Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy
- (2018) Sebastian Rauer et al. NEUROLOGY
- Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
- (2018) Mika Saarela et al. NEUROLOGY
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- Natalizumab-Associated Primary Central Nervous System Lymphoma
- (2018) Menarvia Nixon et al. World Neurosurgery
- Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis
- (2018) L.J.W. Canham et al. Multiple Sclerosis and Related Disorders
- A case of immune-mediated encephalitis related to daclizumab therapy
- (2018) Michael Devlin et al. Multiple Sclerosis Journal
- Immune-mediated encephalitis with daclizumab: The final nail
- (2018) Thomas Williams et al. Multiple Sclerosis Journal
- Sarcoidosis following alemtuzumab treatment for multiple sclerosis
- (2018) Mark D Willis et al. Multiple Sclerosis Journal
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
- (2018) Sibyl Wray et al. Multiple Sclerosis Journal
- Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary progressive Multiple Sclerosis
- (2018) S.L. Hauser et al. Multiple Sclerosis and Related Disorders
- Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
- (2017) Marinella Clerico et al. Expert Opinion On Drug Safety
- Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
- (2017) Jagannadha Avasarala et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Alemtuzumab and de novo pulmonary arterial hypertension: A potential association?
- (2017) Laura Beaumier et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
- (2017) Aiden Haghikia et al. LANCET NEUROLOGY
- Ocrelizumab in multiple sclerosis: markers and mechanisms
- (2017) Reinhard Hohlfeld et al. LANCET NEUROLOGY
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
- (2017) Cyra E Leurs et al. Multiple Sclerosis Journal
- Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
- (2017) Adam F Carpenter et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
- (2017) Ingrid Meinl et al. Multiple Sclerosis Journal
- Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
- (2017) Jeffrey M. Gelfand et al. Neurotherapeutics
- Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?
- (2017) E.K. Van Obberghen et al. REVUE NEUROLOGIQUE
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
- (2017) María Inés Gaitán et al. JAMA Neurology
- Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
- (2017) Cyra E Leurs et al. Multiple Sclerosis Journal
- Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
- (2017) Adam F Carpenter et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
- (2017) Ingrid Meinl et al. Multiple Sclerosis Journal
- Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
- (2017) Aaron E. Miller Therapeutic Advances in Neurological Disorders
- Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
- (2017) Cristina Guarnera et al. Therapeutics and Clinical Risk Management
- Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
- (2017) Jonas Graf et al. Annals of Clinical and Translational Neurology
- Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
- (2017) Jenny Link et al. PLoS One
- High cumulative JC virus seroconversion rate during long-term use of natalizumab
- (2016) A. Vennegoor et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study
- (2016) A. Miclea et al. JOURNAL OF NEUROLOGY
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS
- (2016) Steffen Pfeuffer et al. NEUROLOGY
- Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate
- (2016) Flaminia Purchiaroni et al. NEUROLOGY
- Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis
- (2016) Heidi N. Beadnall et al. NEUROLOGY
- PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
- (2016) Klaus Lehmann-Horn et al. NEUROLOGY
- Malignancies after mitoxantrone for multiple sclerosis
- (2016) Mathias Buttmann et al. NEUROLOGY
- Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod
- (2016) Amy K. Forrestel et al. JAMA Neurology
- Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
- (2016) Horst Penkert et al. JAMA Neurology
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)
- (2016) Axel Meissner et al. Multiple Sclerosis and Related Disorders
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- (2016) Giancarlo Comi et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases
- (2016) Zaidoon Al-Jaderi et al. Frontiers in Immunology
- Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis
- (2016) Imke Metz et al. Acta Neuropathologica Communications
- Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
- (2015) Athina Papadopoulou et al. Expert Opinion On Drug Safety
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
- (2015) Daniela Rau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
- (2015) Hongxiu Luo et al. JOURNAL OF NEUROLOGY
- Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?
- (2015) Masahiro Mori JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
- (2015) Per Soelberg Sorensen et al. Therapeutic Advances in Neurological Disorders
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
- (2014) A. Gueguen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Dimethyl fumarate associated lymphopenia in clinical practice
- (2014) Erin E Longbrake et al. Multiple Sclerosis Journal
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
- (2014) C. Warnke et al. NEUROLOGY
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
- (2014) Paul Emery et al. PLoS One
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Progressive multifocal leukoencephalopathy in autoimmune diseases
- (2012) Elisabeth Palazzo et al. JOINT BONE SPINE
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
- (2012) Joshua Safran Therapeutics and Clinical Risk Management
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
- (2011) Jens Ingwersen et al. CLINICAL IMMUNOLOGY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
- (2011) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings
- (2011) Magnhild Sandberg-Wollheim et al. Multiple Sclerosis Journal
- Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
- (2011) Aaron Boster et al. Therapeutic Advances in Neurological Disorders
- Late-Onset Neutropenia After Rituximab Treatment
- (2010) Ofir Wolach et al. MEDICINE
- Sphingosine-1-phosphate receptor signalling in the heart
- (2009) C. K. Means et al. CARDIOVASCULAR RESEARCH
- Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice
- (2009) Ryou Fukushima et al. CONGENITAL ANOMALIES
- Interferon- mechanisms of action in multiple sclerosis
- (2009) S. Dhib-Jalbut et al. NEUROLOGY
- Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
- (2008) Megan Rahmlow et al. ARCHIVES OF NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Demko et al. ONCOLOGIST
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started